First-of-its-kind precision medicine test to predict a cancer patient’s response to an Immune Checkpoint Inhibitor (ICI)
Study to evaluate effectiveness of hypoglossal nerve stimulation
Cantex also plans to initiate Phase 2 clinical trials exploring the therapeutic effect of azeliragon in pancreatic and breast cancers.
Keytruda plus Lenvima is also approved in the U.S. and Europe for the first-line treatment of adult patients with advanced RCC.
Jardiance is the first and only heart failure therapy to demonstrate a statistically significant risk reduction in cardiovascular death or hospitalization for heart failure, regardless of ejection fraction
It is a Phase 3 ready anti-myostatin adnectin for Spinal Muscular Atrophy (SMA).
Fyarro added to NCCN guidelines as the only preferred mTOR inhibitor to treat malignant PEComa
Collaboration in the industry needs to be institutionalised to drive the growth.
New InterStim X system provides 10 to 15 years of battery life without the need to recharge
Revotek announced that it has received clearance from the National Health Commission of China to begin a clinical study in the West China Hospital, Chengdu, with its first stem cell 3D bioprinting product, REVOVAS.
Subscribe To Our Newsletter & Stay Updated
